Study on Cognitive Effects of Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer

What this Trial Is About

Researchers are evaluating cognitive function in patients recently diagnosed with advanced epithelial ovarian cancer who are undergoing neoadjuvant chemotherapy. The study aims to assess various aspects of cognition, including patient-reported outcomes and objective cognitive tests, over a period of approximately 10 months. This research helps understand how chemotherapy might affect learning, memory, processing speed, and executive function in this patient group. Participants will receive neoadjuvant chemotherapy typically including carboplatin and paclitaxel, with possible alternatives or additional maintenance treatments like bevacizumab or PARP inhibitors as part of their standard care. Assessments occur at baseline, after three cycles of chemotherapy, at the end of adjuvant therapy or treatment change, and six months post-treatment. Patient-reported outcomes are collected using surveys such as FACT-O and FACT-Cog, while cognitive function is evaluated through tests like the Rey Verbal Learning Test, Trail Making Test, and Controlled Oral Word Association Test. During the study, participants will complete cognitive and health assessments at multiple time points up to 10 months. These include the Mini Mental State Exam, Patient Health Questionnaire-2, and various cognitive tests to measure learning, memory, processing speed, and executive function. Distress levels are also monitored through routine clinical screenings. The study tracks changes over time to better understand cognitive impact and quality of life during and after chemotherapy.

Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer